Statin therapy, lipid levels, C-reactive protein and the survival of patients with angiographically severe coronary artery disease

Journal of the American College of Cardiology

Volumn 36, Issue 6, 2000, Pages 1774-1780

  Horne, Benjamin D ^a   Muhlestein, Joseph B ^a,b   Carlquist, John F ^a,b   Bair, Tami L ^a   Madsen, Troy E ^a   Hart, Noal I ^a   Anderson, Jeffrey L ^b  

^a LDS HOSPITAL   (United States)

^b UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN;

ADULT; AGE; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIAGNOSTIC VALUE; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE EJECTION FRACTION; HEART PROTECTION; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RISK FACTOR; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES;

AGED; ANTICHOLESTEREMIC AGENTS; C-REACTIVE PROTEIN; CORONARY DISEASE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPOPROTEINS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK FACTORS; STROKE VOLUME; VENTRICULAR FUNCTION, LEFT;

EID: 0034669445     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(00)00950-5     Document Type: Article

References (37)

1. Dyslipidemia and other risk factors for coronary artery disease
2. Serum cholesterol, blood pressure, cigarette smoking and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group
3. The cholesterol facts: A summary of the evidence relating dietary fats, serum cholesterol and coronary, heart disease. A joint statement by the American Heart Association and the National Heart, Lung and Blood Institute. Commissioned by the Task Force on Cholesterol Issues, American Heart Association
4. Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men
5. C-reactive protein and its relation to cardiovascular risk factors: A population-based cross-sectional study
6. Inflammation, atherosclerosis and ischemic events - Exploring the hidden side of the moon
7. Production of C-reactive protein and risk of coronary events in stable and unstable angina
8. Evaluation of C-reactive protein, an inflammatory marker, and infectious serology as risk factors for coronary artery disease and myocardial infarction
9. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining the risk of first myocardial infarction
10. Randomized trial of cholesterol lowering in 4,444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
11. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group
12. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators
13. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
14. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS - Air Force/Texas Coronary Atherosclerosis Prevention Study
15. Statins do more than just lower cholesterol
16. Antiatherothrombotic properties of statins. Implications for cardiovascular event reduction
17. The HELP system: A review of clinical applications in infectious diseases and antibiotic use
18. Inflammation, pravastatin and the risk of coronary events after myocardial infarction in patients with average cholesterol levels
19. Plasma homocysteine levels and mortality in patients with coronary artery disease
20. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Interventional trial
21. Coronary, artery disease/myocardial infarction: Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: The Regression Growth Evaluation Statin Study (REGRESS)
22. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)
23. Percentage change rather than plasma level of LDL-cholesterol determines therapeutic response in coronary heart disease
24. Inhibitor of proliferation of arterial smooth muscle cells by fluvastatin
25. Direct vascular effects of HMG-CoA reductase inhibitors
26. Simvastatin, a potent HMG-CoA reductase inhibitor, inhibits the proliferation of human and bovine endothelial cells in vitro
27. Hyperlipidemia and coronary disease: Correction of the increased thrombogenic potential with cholesterol reduction
28. Effects of pravastatin sodium and simvastatin on plasma fibrinogen level and blood rheology in type II hyperlipoproteinemia
29. Pravastatin therapy in hyperlipidemia: Effects on thrombus formation and the systemic hemostatic profile
30. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with coronary artery disease
31. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease
32. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion
33. Effects of different inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, pravastatin sodium and simvastatin on sterol synthesis and immunological functions in human lymphocytes in vitro
34. C-reactive protein and cytomegalovirus antibody levels predict mortality in patients with angiographically defined coronary artery disease
35. Effect of statins on C-reactive protein in patients with coronary artery disease
36. Long-term effects of pravastatin on plasma concentration of C-reactive protein